Jagmeet S Dhingra 1/2/2013.  45 yo hispanic male with long standing cirrhosis due to HepC and Alcohol  Multiple admissions for hepatic encephalopathy.

Slides:



Advertisements
Similar presentations
Learning objectives To understand the pathophysiologic basis for vasoactive therapies for HRS To become familiar with the diagnostic criteria for HRS To.
Advertisements

Acute Liver Failure.
Girish Singhania N Engl J Med 2012 Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome.
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Renal Megan McClintock, RN, MS 10/27/11 “TO PEE IS TO LIVE”
 Brian Torski, DO, Internal Medicine PGY-1.  Overview of Hepatorenal Syndrome o Pathophysiology o Diagnosis o Classification o Prevention and Treatment.
SLOW- COOKING THE BEANS “OR, HOW TO STOP WORRYING AND APPLY SOME LOVE TO THE KIDNEYS” AN APPROACH TO CKD SARA KATE LEVIN, MD JANUARY 2014.
Management of ascites in patients with cirrhosis Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.
National Institute for Health and Clinical Excellence.
Severe Sepsis Initial recognition and resuscitation
Complications of Liver Cirrhosis Ayman Abdo MD, AmBIM, FRCPC.
The hepatorenal syndrome. Assessing kidney function in pts with cirrhosis  Cr assays are subject to interference by chromogens, bilirubin being the major.
Liver pathology: CIRRHOSIS
Heart Failure, HF CHF develops when plasma volume increases and fluid accumulates in the lungs, abdominal organs (liver especially), and peripheral tissues.
By: Janel Canty RNS (Osborn, 2010). Objectives To understand Hyponatremia To be able to recognize hyponatremia in a clinical setting Be able to apply.
Fluids and Electrolytes
IV CURSO PARA RESIDENTES DE LA AEEH DIAGNÓSTICO Y TRATAMIENTO DE LAS ENFERMEDADES HEPÁTICAS Barcelona, de Octubre de 2013 ASCITIS Y SINDROME HEPATORRENAL.
HEPATORENAL SYNDROME – LIVER PERSPECTIVE Dr. S. Shivakumar M.D., Addl. Professor of Medicine, Govt.Stanley Medical College, Chennai – By.
HEPATO renal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine.
Diabetic Ketoacidosis DKA)
Hepatorenal Syndrome Dr Allister J Grant Leicester Liver Unit
Dose Adjustment in Renal and Hepatic Disease
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Creatinine (mg/dL) MonthsWeeks Therapeutic paracentesis Cefotaxime Type-2 HRSType-1 HRS Encephalopathy Jaundice CLINICAL TYPES.
PreRenal Acute Kidney Injury Mini-Lecture David Aymond 2/21/2012.
Acetaminophen Toxicity. Overview Principle pf the disease Clinical features Diagnosis Management.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Copyright 2008 Society of Critical Care Medicine
Spontaneous Bacterial Peritonitis Katherine Yu May 2014.
Medical management of hepatorenal syndrome Nephrol Dial Transplant (2012) 27: 34–41 doi: /ndt/gfr736 Andrew Davenport1, Jawad Ahmad2, Ali Al-Khafaji3,
Dr. Aya M. Serry Renal Failure Renal failure is defined as a significant loss of renal function in both kidneys to the point where less than 10.
Complications of Liver Cirrhosis
Acute Renal Failure Doç. Dr. Mehmet Cansev. Acute Renal Failure Acute renal failure (ARF) is the rapid breakdown of renal (kidney) function that occurs.
Treatment of Metabolic Acidosis in CKD Presented by Pharmacist: Ola Mohammad Elkersh PharmD student
Management of patients with cirrhosis and refractory ascites Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of.
Volume 350: April 15, 2004 Number 16 Management of Cirrhosis and Ascites Pere Ginès, M.D., Andrés Cárdenas, M.D., Vicente Arroyo, M.D., and Juan.
Urinary System Diseases. Objective To describe the symptoms, causes, and treatments for Kidney Stones, Urinary Tract Infections, and Renal Failure.
Did I do that? Drug-Induced Acute Kidney Injury Krista Rieger, PharmD, BCPS PGY2 Internal Medicine Resident.
Retrospective Monocentric 10-Year Analysis Of Sepsis-Associated Acute Kidney Injury: Impact On Outcome, Dialysis Dose And Residual Renal Function 1 Vincenzo.
N Engl J Med 2010;362: R3 CHAE JUNGMIN/ Prof KIM MYENGGON.
Definition  Is a chronic disease characterized by scaring and necrotic tissue replaced by fibrotic tissue. Resulting in hepatic insufficiency and portal.
Short-term effects of combination of satavaptan, a selective vasopressin V 2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without.
Presentation by JoAnn Czech RN/CDS St. Cloud Hospital.
INTERNAL MEDICINE BENJAMIN YIP 4/13/16 Mini Lecture: Hepatorenal Syndrome.
CIRRHOSIS MANAGEMENT FOR HOSPITALISTS Madhav Devani 6/7/16.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
The Kidney in Liver Disease
HEPATORENAL SYNDROME.
Kidney Injury and Liver Disease in the ICU
Liver Disease tutoring Part 2
The Relationship between Postoperative Serum Albumin Level and Organ Dysfunction after Liver Transplantation. Results No differences were found between.
New Diagnostic Criteria and Management of Acute Kidney Injury
Developed by 91 Civil Affairs Presented/modified by 1BCT, 82D ABN DIV
ACUTE LIVER FAILURE Acute liver failure is defined as the rapid development of hepatocellular dysfunction (WITHIN 8 WEEKS OF DISEASE ONSET), specifically.
Dip. Software based statistics-
Hepatorenal Syndrome.
Acute and Chronic Renal Failure
Managing Complications of Cirrhosis
Multiple factors can predispose to decompensation in a patient with cirrhosis. Risk factors for decompensation include: Bleeding Infection Alcohol.
Chapter 15 Shock and Multiple Organ Dysfunction Syndrome
Diuretics, Kidney Diseases Urine R&M
Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise
Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment
Internal medicine L-4 Liver cirrhosis & portal hypertension
Current Controversies and Advances in Hepatorenal Syndrome
Clinical Pharmacokinetics
CLINICAL PRACTICE GUIDELINES FOR MANAGEMENT OF ASCITES, SBP AND HRS
Presentation transcript:

Jagmeet S Dhingra 1/2/2013

 45 yo hispanic male with long standing cirrhosis due to HepC and Alcohol  Multiple admissions for hepatic encephalopathy  Diuretic resistant ascites with therapeutic paracentesis every 2 months  Physical examination suggestive of volume overload with peripheral edema and ascites  Acute rise in Cr to 2.9 in 5 days from a baseline of found on outpatient labs  Baseline BP ’s  On lactulose at home.  Last LVP 1 week ago with 10 liter removal

 What to do and Whats going on. Options 1. I cant believe I am having another crappy night. 2. Do a detailed history and exam 3. Start normal saline at 150cc/hour-he is likely intravascularly depleted 4. Do a diagnostic paracentesis 5. Send of UA, urine lytes along with chemistries 6. Call the renal fellow

 AKI is a relatively frequent problem, occurring in approximately 20% of hospitalized patients with cirrhosis  Renal dysfunction (creatinine and blood urea nitrogen/azotemia) both powerful predictors of death in decompensated cirrhosis.  Higher serum creatinine consistently portends worse survival

 Hospitalized cirrhotic patients 20% present with AKI at admission  70 % develop with AKI during Admission  Patients admitted with SBP 41-56% have AKI  5-6% develop AKI after TIPS  Annals of Hepatology (3)

 During the history you obtain while trying to stay awake, he mentions he has been taking Ibuprofen for knee pain and has also been having some abdominal discomfort. Hasn’t noticed increased stool output on lactulose but they were black yesterday. Abdomen on exam is not tense but does have some generalized tenderness  What next

 Why couldn’t he come to hospital earlier in the day and why do I get all the train wrecks  Start normal saline at 150/hour. He is likely GI bleeding  Do a diagnostic paracentesis. This is likely peritonitis.  Its probably the ibuprofen.  Send of labs and urine studies and start albumin  Call the renal fellow

 Nonsteroidal antiinflammatory drugs may also cause renal failure in patients with cirrhosis, since their kidney function is extremely dependent on renal prostaglandin synthesis.  Patients who have ascites, particularly those with hyponatremia, bacterial infections, gastrointestinal bleeding, or severe sodium retention, are at high risk for renal failure, as are all patients hospitalized for acute decompensation of cirrhosis

 Creatinine is derived from creatine, mostly synthesized by the liver.  Patients with liver disease tend to have lower creatine synthesis and consequently, lower serum creatinine values for any given level of GFR.  These lower values are compounded by the loss of muscle mass that is common in patients with progressive chronic liver disease.  Also have a degree of creatinine dilution caused by the accumulation of peripheral edema and ascites.

 Clinical chemistry laboratories typically measure serum creatinine by a modified Jaffe colorimetric assay, which depends on a color change that can be influenced by noncreatinine chromogens such as bilirubin, particularly with serum bilirubin concentrations >10 mg/dl. This effect of bilirubin reduces the measured creatinine value. Alternative is to measure it enzymatically  Serum creatinine and estimated GFR calculated using serum creatinine overestimate actual kidney function.

 Likewise, an increase in serum creatinine concentration of 0.3 mg/dl (i.e., corresponding to Acute Kidney Injury Network stage 1 AKI) represents a much greater decrease in kidney function in cirrhotic patients compared with others who develop AKI

 Electrolytes and protein should be measured (preferably in 24-hr urine samples) in all patients with renal failure;  Significant proteinuria (>500 mg of protein/day) and urine-sediment abnormalities usually indicate parenchymal renal disease.  A renal biopsy is helpful when parenchymal renal disease is suspected because of proteinuria, hematuria, or both and  is also helpful in deciding on simultaneous kidney transplantation in candidates for liver transplantation;

 Intra-abdominal pressure may be increased in patients with cirrhosis because of the presence of tense ascites.  Although a typical compartment syndrome causing AKI may be associated with intra- abdominal pressures of 18 mmHg or greater, lower pressures can cause renal dysfunction, especially in the setting of systemic hypoperfusion or sepsis. Renal perfusion has been reported to improve after drainage of ascites.  Overzealous removal of ascites, even with colloid replacement, can lead to intravascular hypovolemia and ischemic AKI; Be careful with LVP

 His stool hemoccult turns out to be negative. He forgot to tell you he had also just started iron pills  His paracentesis suggests markedly elevated white count with high amount of polys  His urine sodium is less than 10 with a bland UA and no proteinuria

 It cant be 7 A.M soon enough  Start antibiotics and Albumin infusions  This is HRS due to the low urine sodium. Start midodrine and octreotide right away  He is septic. Given him 2 liter saline bolus and hold his diuretics  Transfer him to ICU for norepinephrine infusion for HRS  Call the renal fellow.

 HRS is a specific form of volume-unresponsive kidney injury in patients with progressive cirrhosis and ascites  Only around 50% of patients treated for HRS with vasoconstrictive agents respond to treatment with a reduction in serum creatinine

 1-year and 5-year probabilities of developing HRS in patients with ascites are approximately 20% and 40%,  Highest in patients with more marked sodium and water retention and marked activation of vasoconstrictive systems.  HRS is divided into two types (1 and 2) based on prognosis and clinical characteristics.  Survival of patients with HRS-1 is shorter than that of patients with HRS-2 (median survival 1.0 versus 6.7 months)

 Bacterial infection  SIRS/Sepsis  GI losses  Diuretics  GI bleeding  LVP  NSAIDs including COX-2  ACE inhibitors

 Presence of ascites is a prerequisite for the diagnosis of HRS because the same mechanisms that lead to ascites formation lead to HRS  HRS have advanced liver disease, as evidenced by the median Child-Pugh score in these patients being 11.2, and their low MAP (median, 74 mmHg), and low serum sodium (median, 127 mEq/L), findings that are consistent with the presence of vasodilatation (low MAP), sodium retention (ascites), water retention (dilutional hyponatremia), and renal vasoconstriction (HRS)

 Baseline SCr is a predictor of HRS reversal  The probability of HRS reversal decreases by 39% for each 1-mg/dL increase in baseline creatinine.  OLT is the only definitive therapy for HRS, only therapy associated with improvement in survival.  Important to try reverse HRS because improving renal function pretransplantation is associated with improved posttransplantation outcomes

 Vasoconstrictors used in the treatment of HRS for periods greater than 3 days are associated with increases in MAP, GFR, and serum sodium and decreases in SCr and plasma renin activity  Noradrenaline, in continuous infusion, has also been shown to ameliorate the hemodynamic /renal abnormalities in HRS as has the combination of midodrine.  They almost always require co administration of albumin

 Method to adjust the dose of vasoconstrictors is by monitoring MAP (an indirect indicator of vasodilatation), a method that has been used for adjusting the dose of midodrine plus octreotide, an alternative to terlipressin (not available in the US)

 The doses of octreotide and midodrine were titrated to obtain an increase in mean arterial pressure of at least 15 mm Hg.  Octreotide was administered subcutaneously at an initial dose of 100 μ g three times daily and then, if necessary,increased to 200 μ g three times daily.  Midodrine was administered orally at an initial dose of 7.5 mg three times daily and then, if need be, increased to 12.5 mg three times daily. In addition, an amount of 20 to 40 g/d of albumin was infused.

 Albumin is administered together with the vasoconstrictor.  The maintenance dose, once the diagnosis of HRS is established and vasoconstrictors are initiated, is 25 to 50 g/day.  Albumin may be discontinued if serum albumin concentration is greater than 4.5 mg/dL and should be withdrawn in case of pulmonary edema.

 In addition to serving as an intravascular volume expander, albumin also has binding sites for free radicals and toxins, and hence, in patients with liver failure, albumin infusions may help by increasing the capacity to bind such toxins

 Although intravenous infusion of crystalloid solutions can usually be safely given to patients with cirrhosis because of their systemic vasodilatation, any fluid bolus that initially expands the intravascular space will subsequently distribute to expand the entire extracellular space, worsening peripheral edema and ascites.  Overzealous fluid administration can also precipitate cirrhotic cardiomyopathy with heart failure and hypoxia because of hepatopulmonary syndrome.

 Treatment can be stopped if SCr does not decrease by at least 50% after 7 days at the highest dose, or if there is no reduction in creatinine after the first 3 days.  In patients with early response, treatment should be extended until reversal of HRS (decrease in creatinine below 1.5 mg/dL) or for a maximum of 14 days.  Vasoconstrictor therapy should be restarted if HRS recurs after discontinuation of therapy.  Once creatinine normalizes, TIPS should be considered, particularly if transplantation is not foreseeable in the near future and the patient has refractory ascites

 Patient is started on albumin infusions and antibiotics. He does not respond to albumin and renal consult is called for worsening creatinine.  A smart renal fellow ( now attending) starts the patient on midodrine octreotide with gradual uptitration of dose without much improvement  Transplant surgery and hepatology say patient not a transplant candidate due to active alcohol abuse

 When do I get off service. This guy is a rock. He will be here forever  Discuss with nephrology about initiating dialysis with worsening volume status  Family meeting and palliative care consult  Discuss with hepatology about TIPS

 In a large study involving 129 cirrhotic patients with varying degrees of baseline renal function, TIPS has been shown to improve renal function.  Patients with pre-treatment serum creatinine levels between 1.2 and 1.9 mg/dL had reduced mean levels of creatinine, from 1.5 to 1.1 mg/dL, and those with pre-TIPS creatinine levels > 2.0 mg/dL showed a reduction from 2.8 to 1.5 mg/dL.

 The prognosis for patients with cirrhosis and renal failure is poor.  The overall survival rate is approximately 50% at 1 month and 20% at 6 months.  Survival rates can differ according to the type of renal failure.  HRS is associated with the worst prognosis.  Type 1 HRS mortality 80% at 2 weeks with 10% 3 month survival  MELD score median survival 1 month if Meld 20 or more and 8 month if Meld less than 20

 The risk of the hepatorenal syndrome is substantial in patients with cirrhosis and spontaneous bacterial peritonitis but may be markedly reduced with the intravenous administration of albumin (1.5 g per kilogram of body weight at diagnosis and 1.0 g per kilogram 48 hours later).  The mechanism by which albumin prevents the hepatorenal syndrome is incompletely understood but may be related to albumin’s positive effects on circulatory function and other effects, such as its antioxidant properties

 Patients with ascitic fluid that contains less than 15 g of protein per liter and who have associated impairment of liver function, renal function, or both (a bilirubin level above 3 mg per deciliter, a Child–Pugh score greater than 10, a serum sodium level below 130 mmol per liter, or a serum creatinine concentration above 1.2 mg per deciliter, the long-term administrationof oral norfloxacin (400 mg per day) reducesthe risk of the hepatorenal syndrome and improves survival

 After informing the patient about his prognosis and outcome and that dialysis will not change his outcome due to his severe liver disease, patient and family decide to go with hospice care. Patient expired 1 week after discharge

 All AKI in Cirrhosis is not HRS  Look for a precipitating cause  Use volume judiciously  Avoid nephrotoxic agents  If starting vasoconstrictors, adjust doses based on repsonse. Do not leave patient on single fixed dose